BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27895116)

  • 1. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
    Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
    J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
    Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
    J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
    Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
    Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
    Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
    Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
    Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
    Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
    Liu X; Dawson DC
    Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.
    Mutyam V; Libby EF; Peng N; Hadjiliadis D; Bonk M; Solomon GM; Rowe SM
    J Cyst Fibros; 2017 Jan; 16(1):24-29. PubMed ID: 27707539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
    Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
    J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
    Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.
    Laselva O; Eckford PD; Bartlett C; Ouyang H; Gunawardena TN; Gonska T; Moraes TJ; Bear CE
    J Cyst Fibros; 2020 Sep; 19(5):717-727. PubMed ID: 31831337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
    Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
    Lin WY; Sohma Y; Hwang TC
    Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators.
    Wang W; Hong JS; Rab A; Sorscher EJ; Kirk KL
    PLoS One; 2016; 11(3):e0152232. PubMed ID: 27007499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.